Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
July 23 -- A director and former chief executive officer of Biolase Inc. is asking the Delaware Court of Chancery to delay the company's annual shareholders' meeting until the court decides whether to order that his slate of director nominees be included on the proxy ballot.
Plaintiff Federico Pignatelli filed his complaint for injunctive relief July 21, asking the court the postpone the annual meeting, scheduled for Aug. 27, 2014, “no more than four weeks.”
Pignatelli, who says he was forced to resign as CEO and chairman last month, wants the court to consider whether his competing slate of directors may stand for election, “the appropriateness of certain statements made, and omissions in, the [c]ompany's [p]roxy statement” regarding Pignatelli, and the validity of defensive actions taken by incumbent directors targeted specifically at him.
Most members of the current board are beholden to the company's largest stockholder, Oracle Partners LP, and are attempting to silence any voice that represents stockholders generally, the complaint alleges.
The months-long battle over board composition already includes a hearing before the Delaware Supreme Court. The state's high court ruled July 12 against Pignatelli, upholding the effectiveness of a director's resignation by an oral statement (Biolase Inc. v. Oracle Partners LP , 2014 BL 167994, Del., No. 270, 2014, 7/12/14) .
In that case, Biolase, directed by Pignatelli as CEO, argued that recently appointed director Paul Clark could not take his board seat because the Feb. 28 resignation of director Alexander Arrow was not done in writing. Pignatelli had nominated Clark and voted to add him to the board, but then opposed him when Clark asked Pignatelli to resign as CEO.
The Delaware Supreme Court held that Arrow could resign from the board by means of an oral statement under Delaware General Corporation Law § 141(b), which meant Clark could remain on the board.
Biolase, based in Irving, Calif., is a maker of dental and medical devices.
On the heels of the state Supreme Court decision, the board pushed Pignatelli from his positions as CEO and chairman, though he continues to serve on the board, according to the complaint.
According to a contract with the company, Pignatelli's name must appear on the proxy statement, but the company has “circumvented” that contractual obligation by recommending that shareholders not approve him, the complaint states.
Further, Pignatelli's slate of nominees were left off the proxy statement because of “a non-substantive, technical reading of [company bylaws] and an inaccurate characterization of the notice nominating” the slate, Pignatelli charges.
The complaint is available at http://www.bloomberglaw.com/public/document/Pignatelli_Federico_vs_Biolase_Inc_et_al_Docket_No_9920_Del_Ch_Ju.
The Supreme Court decision is available at http://www.bloomberglaw.com/public/document/Biolase_Inc_v_Oracle_Partners_LP_No_270_2014_2014_BL_167994_Del_J.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)